arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

AbbVie Inc.

ABBV Health Care Biotechnology: Pharmaceutical Preparations
$285.19
▼ -1.4% Today
as of Oct 22, 16:45 ET
Last 30 days +8.95% Sep 14 → Oct 22
$257.60 $266.05 $274.50 $282.96 $291.41 Sep 14 Sep 22 Sep 29 Oct 07 Oct 14 Oct 22
Open
$284.57
High
$285.74
Low
$278.01
Volume
$6M
Avg Vol
$6M
Mkt Cap
$479.5B
P/E (TTM)
113.26
Beta
—
52w High
$291.40
52w Low
$190.75
Div Yield
—
Shares Out
—

Recent Press Releases & News last 60 days · 25 items

mixed ▲ 2 ● 23 ▼ 0
Oct 21 · 20:45 Zacks neutral
AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors
Oct 21 · 15:18 Insider Monkey neutral
AbbVie vs. AstraZeneca: Which Pharma Giant Has the Stronger Earnings Growth Story?
Oct 21 · 13:20 Motley Fool neutral
AbbVie vs. Bristol Myers Squibb: Faster Growth or Steady Revenue?
▸ Show all 25 press releases & news Free account →

ABBV earnings at a glance

AbbVie Inc. (ABBV) is scheduled to report earnings on Friday, October 30, 2026 before the market opens — in 7 days. Analysts expect earnings per share of $3.77, compared with $1.86 in the same quarter last year (+103%). The options market is pricing a move of about ±1.4% after the report, a range of roughly $281.07 to $289.31 from today's $285.19. Over its last 5 reports the stock rose the next day 2 times and fell 3, moving ±3.4% on average; after the most recent report on Jul 31, 2026 it moved -2.5%. That means options currently expect less movement than ABBV has typically delivered. ABBV beat the consensus EPS estimate in 6 of its last 6 reported quarters. Implied volatility is currently 35%. The share price of $285.19 sits near its 52-week high.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$191
$291
94% of range
Avg surprise (last 6)
+2.3%
Avg reaction (last 5)
-0.9%
40% positive
Latest IV / EM
35%
EM ±1.4% · $270 · Oct 9

Earnings trends

EPS — actual vs estimate Actual Estimate
$0.13$1.01$1.89$2.77$3.65 Actual $0.13Actual $1.14Actual $1.00Actual $0.77Actual $0.77Actual $0.88Actual $2.46Est $2.39Actual $2.97Est $2.89Actual $1.86Est $1.77Actual $2.71Est $2.66Actual $2.65Est $2.62Actual $3.65Est $3.64 MarJunSepMarJunSepMar/2025Jun/2025Sep/20258K8KJun/2026
Revenue vs Net Income Revenue Net income
$0$4.5B$8.9B$13.4B$17.8B Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Fri Jul 31, 2026Jun/2026 $3.65 $3.64 +0.3% +22.6% -2.5% earnings
Wed Apr 29, 20268K 2026-04-29 $2.65 $2.62 +1.1% — +3.1% earnings
Wed Feb 4, 20268K 2026-02-04 $2.71 $2.66 +1.9% — -3.8% earnings
Fri Oct 31, 2025Sep/2025 $1.86 $1.77 +5.1% — -4.5% earnings
Thu Jul 31, 2025Jun/2025 $2.97 $2.89 +2.8% — — earnings
Fri Apr 25, 2025Mar/2025 $2.46 $2.39 +2.9% — +3.2% earnings
Mon Sep 30, 2024Sep 2024 $0.88 — — — — financials
Sun Jun 30, 2024Jun 2024 $0.77 — — — — financials
Sun Mar 31, 2024Mar 2024 $0.77 — — — — financials
Sat Sep 30, 2023Sep 2023 $1.00 — — — — financials
Fri Jun 30, 2023Jun 2023 $1.14 — — — — financials
Fri Mar 31, 2023Mar 2023 $0.13 — — — — financials

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Fri Oct 30, 2026Sep/2026BMO $3.77$1.86 +102.7%

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$16.99B$15.00B—$15.78B$15.42B$13.34B—$14.46B
Cost of revenue$4.29B$4.22B—$5.30B$4.35B$4.00B—$4.21B
Gross profit————————
Operating income$6.43B$3.99B—$1.90B$4.89B$3.73B—$3.83B
Net income$3.61B$695M—$186M$938M$1.29B—$1.56B
EPS (diluted)$2.03$0.39—$0.10$0.52$0.72—$0.88

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$6.57B$9.39B$5.23B$5.63B$6.47B$5.17B$5.52B$7.26B
Inventory$5.13B$5.05B$4.95B$4.94B$4.96B$4.53B$4.18B$4.45B
Total current assets$33.67B$33.53B$29.06B$28.54B$29.26B$27.68B$25.58B$27.79B
Total assets$135.12B$136.46B$133.96B$133.90B$137.18B$136.16B$135.16B$143.42B
Long-term debt————————
Total liabilities————————
Total equity$-5.93B$-6.61B$-3.27B$-2.64B$-138M$1.46B$3.33B$6.07B

Implied volatility — last 90 days

25%37%48%60%72% Jun 07 — IV 32% · EM ±3.0%Jun 08 — IV 31% · EM ±2.6%Jun 09 — IV 32% · EM ±2.3%Jun 10 — IV 36% · EM ±2.1%Jun 11 — IV 43% · EM ±1.8%Jun 15 — IV 29% · EM ±2.1%Jun 16 — IV 32% · EM ±1.9%Jun 17 — IV 37% · EM ±1.5%Jun 19 — IV 28% · EM ±3.0%Jun 22 — IV 32% · EM ±2.7%Jun 23 — IV 31% · EM ±2.2%Jun 24 — IV 29% · EM ±1.7%Jun 25 — IV 36% · EM ±1.5%Jun 29 — IV 30% · EM ±7.2%Jun 30 — IV 31% · EM ±7.1%Jul 01 — IV 37% · EM ±1.6%Jul 03 — IV 28% · EM ±3.1%Jul 06 — IV 32% · EM ±2.7%Jul 07 — IV 31% · EM ±2.2%Jul 08 — IV 30% · EM ±1.8%Jul 09 — IV 35% · EM ±1.4%Jul 13 — IV 29% · EM ±2.4%Jul 14 — IV 28% · EM ±2.1%Jul 15 — IV 34% · EM ±2.0%Jul 16 — IV 37% · EM ±1.6%Jul 20 — IV 30% · EM ±2.5%Jul 21 — IV 29% · EM ±2.1%Jul 22 — IV 30% · EM ±1.8%Jul 23 — IV 38% · EM ±1.6%Jul 27 — IV 56% · EM ±4.7%Jul 28 — IV 59% · EM ±4.3%Jul 29 — IV 72% · EM ±4.3%Jul 30 — IV 68% · EM ±2.8%Aug 03 — IV 34% · EM ±2.9%Aug 04 — IV 33% · EM ±2.4%Aug 05 — IV 40% · EM ±2.3%Aug 06 — IV 33% · EM ±1.4%Aug 10 — IV 28% · EM ±2.3%Aug 11 — IV 26% · EM ±1.9%Aug 12 — IV 28% · EM ±1.7%Aug 13 — IV 31% · EM ±1.3%Aug 17 — IV 28% · EM ±2.4%Aug 18 — IV 30% · EM ±2.2%Aug 19 — IV 29% · EM ±1.7%Aug 20 — IV 29% · EM ±1.2%Aug 24 — IV 30% · EM ±2.5%Aug 25 — IV 31% · EM ±2.3%Aug 26 — IV 37% · EM ±2.2%Aug 27 — IV 29% · EM ±1.2%Aug 31 — IV 30% · EM ±2.5%Sep 01 — IV 29% · EM ±2.1%Sep 02 — IV 31% · EM ±1.8%Sep 03 — IV 29% · EM ±1.2%Sep 07 — IV 28% · EM ±2.4%Sep 08 — IV 26% · EM ±1.9%Sep 09 — IV 29% · EM ±1.7%Sep 10 — IV 31% · EM ±1.3%Sep 14 — IV 29% · EM ±2.4%Sep 15 — IV 32% · EM ±2.3%Sep 16 — IV 32% · EM ±1.9%Sep 17 — IV 33% · EM ±1.4%Sep 21 — IV 28% · EM ±2.4%Sep 22 — IV 29% · EM ±2.1%Sep 23 — IV 33% · EM ±1.9%Sep 24 — IV 29% · EM ±1.2%Sep 28 — IV 30% · EM ±7.2%Sep 29 — IV 29% · EM ±6.8%Sep 30 — IV 30% · EM ±1.8%Oct 01 — IV 25% · EM ±1.1%Oct 06 — IV 25% · EM ±1.8%Oct 07 — IV 30% · EM ±1.8%Oct 08 — IV 35% · EM ±1.4%

Sector peers

NVS
Novartis AG
$273.4B $156.27+1.7%
ABT
Abbott Laboratories
$170.8B $102.51+0.1%
NVO
Novo Nordisk A/S
$169.4B $39.43+0.2%
VRTX
Vertex Pharmaceuticals Incorporated
$128.2B $535.17+4.0%
SNY
Sanofi
$98.0B $41.96+1.4%
REGN
Regeneron Pharmaceuticals, Inc.
$76.4B $819.09+1.4%

ABBV earnings FAQ

When is ABBV's next earnings date?

AbbVie Inc. is expected to report on October 30, 2026, before the market opens.

What is ABBV's expected move for earnings?

Options currently price a move of about ±1.4%, or $4.12 per share either way from $285.19.

How does ABBV stock usually react to earnings?

Across the last 5 reports the average next-day move was ±3.4%, up 2 times and down 3 times.

What EPS are analysts expecting from AbbVie Inc.?

The consensus estimate is $3.77 per share, versus $1.86 a year ago.

What is ABBV's implied volatility?

ABBV's at-the-money implied volatility is about 35% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in